NYSE:OSCR News 24 November 2025 - 9 January 2026

Oscar Health shares traded flat at $16.90 premarket Friday after a 2.6% rally Thursday, as investors watched House action on ACA subsidies and a UBS upgrade. UBS raised Oscar to neutral, citing steadier exchange enrollment. CTO Mario Schlosser sold 76,962 shares this week under a preset plan. The House-passed subsidy bill now moves to the Senate, with negotiations ongoing.

Oscar Health, Inc. (NYSE: OSCR) is back in the spotlight on December 15, 2025, as investors track a rare triple intersection of (1) U.S. health-policy headlines, (2) new analyst coverage and price-target resets, and (3) the most time-sensitive part of Affordable Care Act (ACA) open enrollment. As of the latest available market data, OSCR last traded around $16.63, with a market cap near $4.24 billion and a 52-week range of roughly $11.20 to $22.40. This is not a “set it and forget it” stock. Oscar is tightly linked to the economics of ACA marketplaces—and this week, the ACA story is

Oscar Health, Inc. (NYSE: OSCR) is back under the market’s spotlight on December 11, 2025, as Wall Street adds new coverage, doubles down on long‑term profit targets, and investors digest another bout of volatility in this high‑growth, high‑risk health‑insurtech name. While legacy giants such as American International Group, Inc. (AIG) dominate traditional insurance lines, Oscar is trying to reinvent health coverage for the Affordable Care Act (ACA) era with a tech‑first platform, AI tools, and aggressive geographic expansion. That experiment is playing out in real time in the stock price. Oscar Health stock today: volatile in the mid‑$15s As of

Oscar Health Inc. (NYSE: OSCR) has just delivered one of the wildest weeks in its short public-market life: the stock jumped roughly 35% on hopes that the White House will extend Affordable Care Act (ACA) subsidies, then ran straight into a wall of new downgrades and rising bearish options activity. Investopedia+2Reuters+2 As of the latest close, Oscar shares trade around $16.77, giving the health-tech insurer a market value of roughly $4.4–4.5 billion. That leaves the stock about 30% below its 52‑week high of $23.80 and roughly 50% above its 52‑week low of $11.20. StockAnalysis+1 Below is a deep dive into